Melt and Antisolvent Crystallization Patents: Who Leads and Where Filings Concentrate
Top 5 filers hold 34.6% of the field. 349 of 1,009 records sit with just five assignees, and the top 10 combined reach 53.5% — a steep concentration for a process-chemistry category. Annual filings climbed from 58 in 2017 to a peak of 123 in 2023, then recorded 39 in 2024 — a 62% decline from 2021's 103. Because publication lags filing by roughly 18 months, the 2025 and 2026 figures shown are still incomplete and should not be read as a genuine slowdown yet.
- 1SULZER MANAGEMENT AG108
- 2PFIZER INC76
- 3INFINITY PHARMACEUTICALS INC58
- 4F HOFFMANN LA ROCHE & CO AG56
- 5AMGEN INC51
See the full melt and antisolvent crystallization routes analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions on this landscape
Who holds the most patents in melt and antisolvent crystallization?
One assignee leads the ranked list with 108 records, well ahead of fifth place at 51 and tenth place at 30. The top 5 assignees combined hold 34.6% of all 1,009 records in scope, and the top 10 combined reach 53.5%, so filing is concentrated but not monopolised by a single company. The remaining 46.5% is spread across 90 further ranked assignees, leaving meaningful room for smaller filers.
Is patent filing in this field still growing?
Filing rose from 58 records in 2017 to a peak of 123 in 2023, then recorded 39 in 2024, a 62% decline from 2021's 103. However, publication typically lags filing by around 18 months, so the 2025 and 2026 counts in this dataset are still incomplete and cannot yet be read as a real slowdown. The honest read is that 2023 marks the confirmed peak so far, with the true trajectory of 2024 onward still resolving.
What technology areas dominate crystallization patent filings?
Heterocyclic compounds (IPC class C07D) appear in 60.2% of all 1,009 records, and medicinal preparations (A61K) in 50.5%, confirming that most filing activity is pharmaceutical rather than industrial-bulk chemistry. Therapeutic activity classifications (A61P) cover 40.3% of records. Separation-process classes such as B01D (11.0%) and B01J (3.8%) are comparatively thin, suggesting the process-engineering side of crystallization is less densely claimed than the chemistry side.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Melt and Antisolvent Crystallization Routes covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.